Conclusions
Although median follow-up remains short at only 23 months, PET2 has a high prognostic value. In early-stage patients, a negative PET2 has been associated with no relapses to date (0 to 26). In advanced-stage patients, a positive PET2 resulted in disease progression in 10 of 11 patients thus far. Early interim PET at cycle two of chemotherapy may permit the development of risk-adapted strategies: to reduce intensity/morbidity of therapy in good risk patients and to assist in selection of poor-risk, advance-stage patients for early treatment intensification.
This is a preview of subscription content, log in via an institution to check access.
References
Straus DJ, Portlock CS, Qin J, et al.: Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II and IIIA nonbulky Hodgkin’s disease. Blood 2004, 104:3483–3489 [Epub 2004 Aug 17].
Connors JM: Evoking approaches to primary treatment of Hodgkin’s lymphoma. Hematology 2005, 239–244. Available at http://www.asheducationbook.org. Accessed 7/7/06.
Canellos GP: Chemotherapy alone for management of early Hodgkin’s lymphoma. In ASCO Education Book 2006; 491–493.
Yahalom J: Early-stage Hodgkin’s lymphoma should be managed with combined modality therapy. In ASCO Education Book 2006; 499–503.
Rights and permissions
About this article
Cite this article
Portlock, C.S. FDG-PET after two cycles of chemotherapy predicts treatment failure and Progression-free survival in Hodgkin’s lymphoma. Curr Oncol Rep 8, 356–357 (2006). https://doi.org/10.1007/s11912-006-0058-9
Issue Date:
DOI: https://doi.org/10.1007/s11912-006-0058-9